Cargando…
Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia
The success of tyrosine kinase inhibitors in treating chronic myeloid leukemia highlights the potential of targeting oncogenic kinases with small molecules. By using drug activity profiles and individual patient genotypes, one can guide personalized therapy selection for patients with resistance.
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318205/ https://www.ncbi.nlm.nih.gov/pubmed/25316524 http://dx.doi.org/10.1186/s13059-014-0461-8 |
| _version_ | 1782355822680997888 |
|---|---|
| author | Eiring, Anna M Deininger, Michael W |
| author_facet | Eiring, Anna M Deininger, Michael W |
| author_sort | Eiring, Anna M |
| collection | PubMed |
| description | The success of tyrosine kinase inhibitors in treating chronic myeloid leukemia highlights the potential of targeting oncogenic kinases with small molecules. By using drug activity profiles and individual patient genotypes, one can guide personalized therapy selection for patients with resistance. |
| format | Online Article Text |
| id | pubmed-4318205 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-43182052015-02-06 Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia Eiring, Anna M Deininger, Michael W Genome Biol Review The success of tyrosine kinase inhibitors in treating chronic myeloid leukemia highlights the potential of targeting oncogenic kinases with small molecules. By using drug activity profiles and individual patient genotypes, one can guide personalized therapy selection for patients with resistance. BioMed Central 2014-09-17 2014 /pmc/articles/PMC4318205/ /pubmed/25316524 http://dx.doi.org/10.1186/s13059-014-0461-8 Text en © Eiring and Deininger; licensee BioMed Central Ltd. 2014 The licensee has exclusive rights to distribute this article, in any medium, for 12 months following its publication. After this time, the article is available under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Review Eiring, Anna M Deininger, Michael W Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia |
| title | Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia |
| title_full | Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia |
| title_fullStr | Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia |
| title_full_unstemmed | Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia |
| title_short | Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia |
| title_sort | individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia |
| topic | Review |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318205/ https://www.ncbi.nlm.nih.gov/pubmed/25316524 http://dx.doi.org/10.1186/s13059-014-0461-8 |
| work_keys_str_mv | AT eiringannam individualizingkinasetargetedcancertherapytheparadigmofchronicmyeloidleukemia AT deiningermichaelw individualizingkinasetargetedcancertherapytheparadigmofchronicmyeloidleukemia |